RS64304B1 - Betahistin, ili njegova farmaceutski prihvatljiva so, i inhibitor monoaminske oksidaze, za upotrebu u lečenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta - Google Patents
Betahistin, ili njegova farmaceutski prihvatljiva so, i inhibitor monoaminske oksidaze, za upotrebu u lečenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjektaInfo
- Publication number
- RS64304B1 RS64304B1 RS20230485A RSP20230485A RS64304B1 RS 64304 B1 RS64304 B1 RS 64304B1 RS 20230485 A RS20230485 A RS 20230485A RS P20230485 A RSP20230485 A RS P20230485A RS 64304 B1 RS64304 B1 RS 64304B1
- Authority
- RS
- Serbia
- Prior art keywords
- betahistine
- vertigo
- symptoms
- prevention
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1704949.5A GB201704949D0 (en) | 2017-03-28 | 2017-03-28 | Combination treatment |
GBGB1711677.3A GB201711677D0 (en) | 2017-07-20 | 2017-07-20 | Combination treatment |
EP18715909.0A EP3600276B1 (en) | 2017-03-28 | 2018-03-28 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject |
PCT/GB2018/050822 WO2018178670A1 (en) | 2017-03-28 | 2018-03-28 | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject |
Publications (1)
Publication Number | Publication Date |
---|---|
RS64304B1 true RS64304B1 (sr) | 2023-07-31 |
Family
ID=61906770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20230485A RS64304B1 (sr) | 2017-03-28 | 2018-03-28 | Betahistin, ili njegova farmaceutski prihvatljiva so, i inhibitor monoaminske oksidaze, za upotrebu u lečenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta |
Country Status (13)
Country | Link |
---|---|
US (3) | US11083718B2 (sr) |
EP (2) | EP4234022A3 (sr) |
DK (1) | DK3600276T3 (sr) |
ES (1) | ES2950452T3 (sr) |
FI (1) | FI3600276T3 (sr) |
HR (1) | HRP20230735T1 (sr) |
HU (1) | HUE062729T2 (sr) |
LT (1) | LT3600276T (sr) |
PL (1) | PL3600276T3 (sr) |
PT (1) | PT3600276T (sr) |
RS (1) | RS64304B1 (sr) |
SI (1) | SI3600276T1 (sr) |
WO (1) | WO2018178670A1 (sr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI3600276T3 (fi) | 2017-03-28 | 2023-06-29 | Intrabio Ltd | Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa |
GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
PT2293794E (pt) | 2008-05-27 | 2013-07-10 | Univ Melbourne | Métodos de tratamento de mamíferos com disfunções da trompa de eustáquio |
EP2491930A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
FI3600276T3 (fi) * | 2017-03-28 | 2023-06-29 | Intrabio Ltd | Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa |
-
2018
- 2018-03-28 FI FIEP18715909.0T patent/FI3600276T3/fi active
- 2018-03-28 HR HRP20230735TT patent/HRP20230735T1/hr unknown
- 2018-03-28 PL PL18715909.0T patent/PL3600276T3/pl unknown
- 2018-03-28 ES ES18715909T patent/ES2950452T3/es active Active
- 2018-03-28 LT LTEPPCT/GB2018/050822T patent/LT3600276T/lt unknown
- 2018-03-28 PT PT187159090T patent/PT3600276T/pt unknown
- 2018-03-28 RS RS20230485A patent/RS64304B1/sr unknown
- 2018-03-28 DK DK18715909.0T patent/DK3600276T3/da active
- 2018-03-28 HU HUE18715909A patent/HUE062729T2/hu unknown
- 2018-03-28 EP EP23176227.9A patent/EP4234022A3/en active Pending
- 2018-03-28 EP EP18715909.0A patent/EP3600276B1/en active Active
- 2018-03-28 WO PCT/GB2018/050822 patent/WO2018178670A1/en unknown
- 2018-03-28 SI SI201830944T patent/SI3600276T1/sl unknown
- 2018-03-28 US US16/499,087 patent/US11083718B2/en active Active
-
2021
- 2021-08-06 US US17/396,064 patent/US11690830B2/en active Active
-
2023
- 2023-05-19 US US18/320,761 patent/US20230285373A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210085659A1 (en) | 2021-03-25 |
LT3600276T (lt) | 2023-08-10 |
PT3600276T (pt) | 2023-07-11 |
DK3600276T3 (da) | 2023-07-10 |
EP3600276B1 (en) | 2023-05-31 |
FI3600276T3 (fi) | 2023-06-29 |
US11690830B2 (en) | 2023-07-04 |
EP4234022A3 (en) | 2023-10-04 |
PL3600276T3 (pl) | 2023-08-21 |
EP3600276A1 (en) | 2020-02-05 |
HUE062729T2 (hu) | 2023-12-28 |
US20230285373A1 (en) | 2023-09-14 |
EP4234022A2 (en) | 2023-08-30 |
WO2018178670A1 (en) | 2018-10-04 |
US11083718B2 (en) | 2021-08-10 |
SI3600276T1 (sl) | 2023-08-31 |
US20210361632A1 (en) | 2021-11-25 |
ES2950452T3 (es) | 2023-10-10 |
HRP20230735T1 (hr) | 2023-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288231A (en) | An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts. | |
PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
IL282487A (en) | TYK2 inhibitors and their use | |
SG11202013231SA (en) | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF | |
IL268327A (en) | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases | |
IL283409A (en) | tyk2 inhibitors and uses thereof | |
PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
IL282090A (en) | tyk2 inhibitors and uses thereof | |
MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
IL271728A (en) | Materials, uses and treatment methods | |
EP3541185C0 (en) | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | |
IL273922A (en) | D-amino acid oxidase inhibitors and their therapeutic uses | |
HUE062729T2 (hu) | Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
NZ733451A (en) | Combination therapy for pulmonary hypertension | |
HK1247917A1 (zh) | 與金屬和/或自由基螯合構型有關的鄰伯二胺,及其抗羰基和氧化應激的活性,及其用途 | |
WO2016126572A3 (en) | Glucosylceramide synthase inhibitors and therapeutic methods using the same | |
GB201519258D0 (en) | Newly identified wnt/beta-catenin signal transduction inhibitors and the use thereof in the treatment or prevention of diseases and conditions. | |
HK1246205A1 (zh) | 在預防和/或治療皮膚損傷中使用的至少一種蛋白酶抑制劑和至少一種活性成分的組合 | |
NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
IL247616B (en) | Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit | |
IL290328A (en) | Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate cancer | |
GEP20197038B (en) | Combination of at least one protease inhibitor and at least one active principle for use in the prevention and/or treatment of skin lesions | |
ZA201600894B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes |